SAN DIEGO, July 17, 2023 /PRNewswire/ — Halozyme Therapeutics, Inc. (NASDAQ: HALO) (“Halozyme”) today announced that argenx reported positive topline data from the ADHERE study evaluating VYVGART® Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) with ENHANZE® in adults with chronic inflammatory demyelinating polyneuropathy (CIDP). The study met its primary endpoint (p=0.000039) demonstrating…Read More
Positive Topline Data Reported from argenxs ADHERE Study of VYVGART Hytrulo with Halozymes ENHANZE Drug Delivery Technology in Patients with Chronic Inflammatory Demyelinating Polyneuropathy
